The qPCR-based test was shown to differentiate cancerous and non-cancerous tissue and predict biochemical recurrence, and can be used on small, degraded samples.
The revenue increase was driven by increased sales of Epigenomics recently approved colorectal cancer screening test Epi proColon.
Two researchers, who have both received grants from Epigenomics, noted in a JAMA letter that the USPSTF did not use data on the FDA-approved version of the test.
The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.
The company said orders are increasing for its blood-based colorectal cancer screening test Epi proColon, which has been rolled out in Europe, China, and the US.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.
The firm could begin to see its product sales increase following the FDA's approval of its colorectal cancer screening test in April.
The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.
The approval comes after the FDA twice asked the company to provide additional data around the test's ability to boost screening compliance.
The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.